- Home
- OCS vs ADPT Comparison
OCS vs ADPT Comparison
Compare OCS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- ADPT
- Stock Information
- Founded
- OCS 2003
- ADPT 2009
- Country
- OCS Switzerland
- ADPT United States
- Employees
- OCS N/A
- ADPT 709
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCS Health Care
- ADPT Health Care
- Exchange
- OCS Nasdaq
- ADPT Nasdaq
- Market Cap
- OCS 706.3M
- ADPT 749.7M
- IPO Year
- OCS N/A
- ADPT 2019
- Fundamental
- Price
- OCS $14.14
- ADPT $5.08
- Analyst Decision
- OCS Strong Buy
- ADPT Buy
- Analyst Count
- OCS 5
- ADPT 4
- Target Price
- OCS $29.20
- ADPT $6.50
- AVG Volume (30 Days)
- OCS 73.4K
- ADPT 1.1M
- Earning Date
- OCS 11-07-2024
- ADPT 11-07-2024
- Dividend Yield
- OCS N/A
- ADPT N/A
- EPS Growth
- OCS N/A
- ADPT N/A
- EPS
- OCS N/A
- ADPT N/A
- Revenue
- OCS $1,027,571.00
- ADPT $177,282,000.00
- Revenue This Year
- OCS $4.38
- ADPT $3.82
- Revenue Next Year
- OCS $905.09
- ADPT $20.38
- P/E Ratio
- OCS N/A
- ADPT N/A
- Revenue Growth
- OCS N/A
- ADPT N/A
- 52 Week Low
- OCS $9.60
- ADPT $2.28
- 52 Week High
- OCS $18.00
- ADPT $6.70
- Technical
- Relative Strength Index (RSI)
- OCS 37.01
- ADPT 47.04
- Support Level
- OCS $16.44
- ADPT $5.09
- Resistance Level
- OCS $18.00
- ADPT $6.70
- Average True Range (ATR)
- OCS 0.68
- ADPT 0.46
- MACD
- OCS -0.46
- ADPT 0.00
- Stochastic Oscillator
- OCS 3.50
- ADPT 24.48
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).